Zambia Approves Lenacapavir, Expanding HIV Prevention Options
Table of Contents
Lusaka, Zambia – November 8, 2025 – Zambia has approved Lenacapavir, a long-acting injectable antiretroviral (ARV) medication, for HIV prevention, marking a important step forward in teh countryS efforts to combat the HIV/AIDS epidemic. The approval positions Zambia as the second African nation, following South Africa, to offer this innovative prevention technology. https://www.unaids.org/en/news-and-resources/press-centre/press-release/south-africa-approves-lenacapavir-long-acting-hiv-prevention
Minister of Health Elijah muchima announced the approval on Friday, emphasizing the government’s commitment to ending HIV as a public health threat by 2030. This commitment is being realized through the introduction of advanced prevention methods. https://www.zambia.gov.zm/news/zambia-approves-lenacapavir-hiv-prevention
What is Lenacapavir and Why is it Important?
Lenacapavir is a first-in-class capsid inhibitor administered as an injection once every six months. Unlike daily oral PrEP (pre-exposure prophylaxis) or other injectable options requiring monthly governance,Lenacapavir offers sustained protection against HIV infection with less frequent dosing. This extended dosing interval addresses a critical need for individuals who find it challenging to adhere to daily or frequent medication schedules.
The drug works by interfering with a protein shell, called the capsid, that HIV uses to infect cells. this novel mechanism of action makes it effective against HIV strains resistant to other prevention methods. https://www.gilead.com/news/press-releases/2024/gilead-announces-positive-topline-results-from-phase-3-lenacapavir-study-evaluating-long-acting-hiv-prevention-in-cisgender-men-and-cisgender-women
Who Will Benefit from Lenacapavir in Zambia?
The introduction of Lenacapavir is expected to have a particularly significant impact on several key populations in Zambia, where approximately 30,000 new HIV infections occur annually, disproportionately affecting adolescent girls and young women. https://www.avert.org/professionals/hiv-aids/country-profiles/zambia
Specifically, Lenacapavir will provide a valuable option for:
* Individuals struggling with adherence: Those who find it difficult to take daily pills or remember frequent injections.
* Pregnant and breastfeeding mothers: Offering a safe and effective prevention method during and after pregnancy.
* Men who prefer discreet access: Providing a private and convenient prevention option.
Building on Existing Prevention Efforts
This approval builds upon Zambia’s existing HIV prevention strategies,including the introduction of Cabotegravir,another long-acting injectable ARV,in February 2024. Minister Muchima confirmed that Lenacapavir will be available free of charge to all eligible Zambians, ensuring equitable access to this life-saving prevention tool.
Primary Topic: HIV Prevention in Zambia
Primary Keyword: Lenacapavir
Secondary Keywords: HIV/AIDS, Zambia, ARV, PrEP, long-acting injectable, HIV prevention, Public Health, Cabotegravir, Gilead Sciences.